SOURCE: WayPoint Biomedical, Inc.

October 06, 2005 16:15 ET

WayPoint Completes Agreement With Euro American Marketing & Sales to Distribute WayPoint's Drink Detective™ Product Range Into the US Over the Counter Retail Sector

HUNTINGTON BEACH, CA -- (MARKET WIRE) -- October 6, 2005 -- WayPoint Biomedical, Inc. (OTC: WYPB) has entered into an agreement with Scottsdale, Arizona-based Euro American Marketing & Sales to distribute and market WayPoint's new Drink Detective™ product range through their extensive network of over 50 different retail brokers into the OTC retail arena.

WayPoint's Director of Sales and Marketing, Phill Richer, states, "Euro American is well established and well respected in the retail sector and we are fortunate to have them working with us. We are currently sending out product information packets to all of their rep groups, and we are hoping to see our first sales within the next three to four weeks."

About Euro American Marketing & Sales:

Euro American works with an established sales network of 14 different broker firms with a collective complement of over 50 individual sales personnel, located strategically throughout the nation. The well respected broker group has been assembled through trial and error over a 30-year timeframe and they are some of the best in the business. They also have a global military broker that covers all PXs and Commissaries. Euro American's total drug, food and mass merchandise network includes 82 headquarter accounts and approximately 40,000 different outlets. Euro American also has strong broker representation and retail accounts throughout Europe. For more information on Euro American Marketing & Sales visit www.euroamericanmarketing.com.

About WayPoint Biomedical:

WayPoint Biomedical, Inc., a wholly owned subsidiary of WayPoint Biomedical Holdings, Inc. (OTC: WYPB), is an innovative biomedical technology firm, specializing in diagnostic tests and devices for screening and monitoring human health, fitness and environment. The Company develops and markets cutting-edge disposable rapid tests that offer both a preliminary diagnostic screen to specific conditions, along with a future path for consumers, medical providers, and first responders to follow regarding their health status or environmental condition. WayPoint's unique and affordable home-based and on-site tests are focused on detecting the cause of a disease or pathogen, as opposed to determining the symptom; becoming a part of the solution to help reverse the escalating cost of Healthcare. The Company's primary target sectors are the Over the Counter (OTC) Self-Testing Market, the Diagnostic Point of Care (POC) Testing Market, and the Homeland Security & Defense Market; three of the fastest growing areas in all of diagnostic medicine and science. For more information on WayPoint Biomedical visit www.waypointbiomedical.com, www.drinkdetectiveusa.com.

Included in this release are certain "forward-looking'' statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding WayPoint's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to WayPoint's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. WayPoint Biomedical does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.

Contact Information